Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust SMID Rising Dividend Achievers UCITS ETF 05.12.2025 SDVY.LN IE0001R850E1 10,879,007.00 USD 249,426,820.94   22.927  ...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), een internationaal oncologiebedrijf, maakte vandaag nieuwe gegevens bekend over sonrotoclax, een onderzoeks-BCL2-remmer van de nieuwe generatie, die belangrijk klinisch voordeel aantoonden als monotherapie en in combinatie bij behandeling van B-cel maligniteiten. Deze gegevens werden voorgesteld tijdens de 67e Annual Meeting & Exposition van de ASH (American Society of Hematology) in Orlando,...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Growth Strength UCITS ETF 05.12.2025 FTGS.LN IE000YZLMXT9   25,002.00 USD    558,469.31   22.337  ...

LONDON--(BUSINESS WIRE)--  08 December 2025 YOUNG & CO.’S BREWERY, P.L.C. Transaction in own shares Young & Co.’s Brewery, P.L.C. (the “Company”) announces that on 05 December 2025, in accordance with the terms of its share buyback programme announced by the Company on 17 November 2025 (the “Share Buyback Programme”), it has purchased the following Non-voting ordinary shares of 12.5 pence each (“Non-voting Shares” and the “Purchased Shares”) in the Company through Peel Hunt LLP (“Peel H...

BOSTON--(BUSINESS WIRE)--PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis...

LONDON--(BUSINESS WIRE)--  Pershing Square Holdings, Ltd. Announces Transactions in Own Shares - 5 December 2025 Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (“PSH”) today announced that it has purchased, through PSH’s agent, Jefferies International Limited (“Jefferies”), the following number of PSH’s Public Shares of no par value (ISIN Code: GG00BPFJTF46) (the "Shares"): Total Buyback   Ticker/s: PSH (LSE); PSHD (LSE) Date of Purchase: 5 December 2025 Number of Public Shares Purchased: 29...

CHAILLÉ-SOUS-LES-ORMEAUX, France--(BUSINESS WIRE)--Hoffmann Green Cement Technologies (ISIN: FR0013451044, Ticker: ALHGR) (“Hoffmann Green Cement” or the “Company”), an industrial player committed to the decarbonation of the construction sector that designs and markets innovative cold produced, clinker-free cements, announces the intensification of its collaboration with Entreprise de Construction et Bâtiment du Littoral (E.C.B.L.), a general construction company based in Rochefort (17). Three...

CHAILLÉ-SOUS-LES-ORMEAUX, France--(BUSINESS WIRE)--Regulatory News: Hoffmann Green Cement Technologies (ISIN : FR0013451044, Mnémo : ALHGR) (« Hoffmann Green Cement » ou la « Société »), acteur industriel engagé dans la décarbonation du secteur de la construction qui conçoit et commercialise des ciments innovants sans clinker, annonce l’intensification de sa collaboration avec l’Entreprise de Construction et Bâtiment du Littoral (E.C.B.L.), entreprise générale du bâtiment implantée à Rochefort...

LONDON--(BUSINESS WIRE)--  First Trust Global Portfolios Management Limited (“FTGPM”) announces the declaration of the quarterly distributions for the following sub-funds of First Trust Global Funds plc, ISIN Fund Name Frequency Dividend per Share IE00BZBW4Z27 First Trust US Equity Income UCITS ETF Class A Quarterly $0.2285 (USD) IE00BWTNMB87 First Trust US Large Cap Core AlphaDEX® UCITS ETF Class B Quarterly $0.1305 (USD) IE00BD9N0445 First Trust United Kingdom AlphaDEX® UCITS ETF Class B Quar...

FRANKFURT, Germany--(BUSINESS WIRE)--Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our r...